<DOC>
	<DOCNO>NCT00087958</DOCNO>
	<brief_summary>The purpose clinical trial determine investigational drug able reduce/shrink advance breast cancer tumor patient longer benefit anthracyclines , taxanes capecitabine .</brief_summary>
	<brief_title>Intravenous RPR109881 Male Female Patients With Advanced Breast Cancer Who Longer Respond Anthracycline , Taxane Capecitabine Treatment</brief_title>
	<detailed_description>All patient trial receive investigational ( chemotherapy ) drug optimal dose determine previous clinical trial . The investigational drug give vein every three week . This drug prevent tumor cell divide , may stop grow die .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>In order eligible trial must : Have diagnosis breast cancer metastatic ( mean cancer spread beyond original location ) recurrence cancer original location remove surgery . Have receive previous treatment anthracyclines ( e.g . doxorubicin [ Adriamycin Doxil ] epirubicin [ Ellence ] ) , taxanes ( paclitaxel [ Taxol Abraxane ] docetaxel [ Taxotere ] ) capecitabine ( e.g . Xeloda ) breast cancer doctor determine treatment longer benefit . Be least 18 year age Not take treatment cancer time enter trial . Not pregnant Additionally , criterion study entry doctor participate study need review detail clinical assessment may need perform ( lab test , CT scan ) . None list . Can discuss doctor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Metastatic breast cancer</keyword>
</DOC>